Neuraminidase inhibitors as antivirals.
The description of the three-dimensional structure of the influenza virus neuraminidase in 1983 opened a new phase in the search for inhibitors of the enzyme. Two compounds in late development (February 1999) have similar levels of potency against influenza A viruses, different routes of administration and, surprisingly, different resistance profiles both in vitro and in vivo.
Colman
P M
PM
Walter and Eliza Hall Institute of Medical Research, P.O. Royal Melbourne Hospital, Melbourne, Vic. 3050, Australia. pcolman@wehi.edu.au
D000998:Antiviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006146:Guanidines; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects*; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D011714:Pyrans; D012794:Sialic Acids / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D053243:Zanamivir
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D009439:Neuraminidase; D053243:Zanamivir